IMO-8400: Development halted

Idera said it will suspend development of IMO-8400 and explore strategic options for it to treat B cell lymphomas. IMO-8400 was in Phase I/II testing to treat DLBCL and Waldenstrom’s macroglobulinemia. The decision was based on clinical data from the trial in Waldenstrom’s macroglobulinemia that did not support it as monotherapy, the “very slow enrollment rate” in DLBCL and the compound’s commercial assessment. No safety concerns were observed in the lymphoma program. ...